Giezen TJ - Search Results

1

Traceability of biologicals: present challenges in pharmacovigilance.

Vermeer NS, Spierings I, Mantel-Teeuwisse AK, Straus SM, Giezen TJ, Leufkens HG, Egberts TC, De Bruin ML. Vermeer NS, et al. Among authors: giezen tj. Expert Opin Drug Saf. 2015 Jan;14(1):63-72. doi: 10.1517/14740338.2015.972362. Epub 2014 Nov 5. Expert Opin Drug Saf. 2015. PMID: 25369769 Review.

2

Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol.

Becker ML, van Uden RCAE, Giezen TJ, Meijer K, Houtenbos I, van den Bemt PMLA. Becker ML, et al. Among authors: giezen tj. Eur J Clin Pharmacol. 2020 Oct;76(10):1457-1464. doi: 10.1007/s00228-020-02930-z. Epub 2020 Jun 10. Eur J Clin Pharmacol. 2020. PMID: 32524154

3

Safety-related regulatory actions for biologicals approved in the United States and the European Union.

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC. Giezen TJ, et al. JAMA. 2008 Oct 22;300(16):1887-96. doi: 10.1001/jama.300.16.1887. JAMA. 2008. PMID: 18940975

4

Pharmacovigilance of biopharmaceuticals: challenges remain.

Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Giezen TJ, et al. Drug Saf. 2009;32(10):811-7. doi: 10.2165/11316550-000000000-00000. Drug Saf. 2009. PMID: 19722725 Review.

5

Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Egberts TC, Blackburn S, Persson I, Leufkens HG. Giezen TJ, et al. Drug Saf. 2009;32(12):1175-87. doi: 10.2165/11318980-000000000-00000. Drug Saf. 2009. PMID: 19916584

6

Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.

Heemstra HE, Giezen TJ, Mantel-Teeuwisse AK, de Vrueh RL, Leufkens HG. Heemstra HE, et al. Among authors: giezen tj. Drug Saf. 2010 Feb 1;33(2):127-37. doi: 10.2165/11319870-000000000-00000. Drug Saf. 2010. PMID: 20082539

7

Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.

Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, Straus SM, Leufkens HG, Egberts TC. Giezen TJ, et al. Drug Saf. 2010 Oct 1;33(10):865-78. doi: 10.2165/11538330-000000000-00000. Drug Saf. 2010. PMID: 20812771

8

Rituximab-induced thrombocytopenia: a cohort study.

Giezen TJ, Mantel-Teeuwisse AK, ten Berg MJ, Straus SM, Leufkens HG, van Solinge WW, Egberts TC. Giezen TJ, et al. Eur J Haematol. 2012 Sep;89(3):256-66. doi: 10.1111/j.1600-0609.2012.01808.x. Epub 2012 Jul 5. Eur J Haematol. 2012. PMID: 22639923

9

Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.

Ingrasciotta Y, Cutroneo PM, Marcianò I, Giezen T, Atzeni F, Trifirò G. Ingrasciotta Y, et al. Drug Saf. 2018 Nov;41(11):1013-1022. doi: 10.1007/s40264-018-0684-9. Drug Saf. 2018. PMID: 29796832 Review.

10

Post-marketing dosing changes in the label of biologicals.

Minnema LA, Giezen TJ, Gardarsdottir H, Egberts TCG, Leufkens HGM, Mantel-Teeuwisse AK. Minnema LA, et al. Among authors: giezen tj. Br J Clin Pharmacol. 2019 Apr;85(4):715-721. doi: 10.1111/bcp.13843. Epub 2019 Feb 16. Br J Clin Pharmacol. 2019. PMID: 30593087 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results